[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Eckert
S
S
Klinik für Kardiologie, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen.
Erdmann
E
E
Lundershausen
R
R
Forst
T
T
Scherbaum
W A
WA
Schnell
O
O
Standl
E
E
Schumm-Draeger
P-M
PM
Tschöpe
D
D
Walter
H
H
Weber
M
M
D000818:Animals; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D050723:Fractures, Bone / Q000209:etiology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000150:complications; D047495:PPAR gamma / Q000187:drug effects / Q000502:physiology; D000077205:Pioglitazone; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D047495:PPAR gamma; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones